Table 1.
Data summary and comparison between patients with and without gastric intestinal metaplasia
| Level |
Baseline no GIM
|
||||
|
Overall
|
No GIM
|
GIM
|
P
value
|
||
| 579 | 441 | 138 | |||
| Follow-up days [median (IQR)] | 885.0 (257.5, 1901.5) | 857.0 (259.0, 1834.0) | 1087.0 (260.5, 2307.3) | 0.247 | |
| Age baseline [median (IQR)] | 58.0 (49.0, 67.8) | 56.0 (46.8, 65.0) | 64.00 (54.0, 72.0) | < 0.001 | |
| Sex (%) | Male | 227 (39.3) | 166 (37.7) | 61 (44.2) | 0.208 |
| Female | 351 (60.7) | 274 (62.3) | 77 (55.8) | ||
| Ethnicity/Race (%) | Caucasian | 85 (15.9) | 73 (18.1) | 12 ( 9.3) | 0.032 |
| AA | 381 (71.5) | 287 (71.0) | 94 (72.9) | ||
| Hispanic | 18 ( 3.4) | 11 ( 2.7) | 7 ( 5.4) | ||
| Other | 49 ( 9.2) | 33 ( 8.2) | 16 (12.4) | ||
| Obesity (%) | BMI < 30 | 261 (56.7) | 191 (53.5) | 70 (68.0) | 0.013 |
| BMI > 30 | 199 (43.3) | 166 (46.5) | 33 (32.0) | ||
| Smoking status (%) | Never | 269 (54.8) | 207 (55.3) | 62 (53.0) | 0.198 |
| Previous | 119 (24.2) | 84 (22.5) | 35 (29.9) | ||
| Current | 103 (21.0) | 83 (22.2) | 20 (17.1) | ||
| Biopsy site (%) | ≤ 2 | 227 (39.2) | 190 (43.1) | 37 (26.8) | 0.001 |
| > 3 | 352 (60.8) | 251 (56.9) | 101 (73.2) | ||
| H. pylori at Baseline (%) | No | 499 (86.2) | 382 (86.6) | 117 (84.8) | 0.686 |
| Yes | 80 (13.8) | 59 (13.4) | 21 (15.2) | ||
| H. pylori at follow-up (%) | No | 536 (92.6) | 413 (93.7) | 123 (89.1) | 0.114 |
| Yes | 43 ( 7.4) | 28 ( 6.3) | 15 (10.9) | ||
| n | 80 | 59 | 21 | ||
| H. pylori at follow up with positive Baseline (%) | No | 65 (81.2) | 48 (81.4) | 17 (81.0) | 1 |
| Yes | 15 (18.8) | 11 (18.6) | 4 (19.0) | ||
| Gastritis (%) | No | 209 (36.1) | 180 (40.8) | 29 (21.0) | < 0.001 |
| Yes | 370 (63.9) | 261 (59.2) | 109 (79.0) | ||
| Ulcer (%) | No | 534 (92.2) | 408 (92.5) | 126 (91.3) | 0.778 |
| Yes | 45 ( 7.8) | 33 ( 7.5) | 12 ( 8.7) | ||
| 81 mg Aspirin Use at Baseline (%) | No | 450 (77.7) | 347 (78.7) | 103 (74.6) | 0.379 |
| Yes | 129 (22.3) | 94 (21.3) | 35 (25.4) | ||
| 81 mg Aspirin use at follow up (%) | No | 453 (78.2) | 359 (81.4) | 94 (68.1) | 0.001 |
| Yes | 126 (21.8) | 82 (18.6) | 44 (31.9) | ||
| PPI usage at baseline (%) | No | 392 (67.7) | 285 (64.6) | 107 (77.5) | 0.006 |
| Yes | 187 (32.3) | 156 (35.4) | 31 (22.5) | ||
| PPI usage at follow up (%) | No | 318 (54.9) | 233 (52.8) | 85 (61.6) | 0.088 |
| Yes | 261 (45.1) | 208 (47.2) | 53 (38.4) | ||
| Blood type (%) | A | 72 (31.2) | 47 (28.7) | 25 (37.3) | 0.317 |
| B | 42 (18.2) | 28 (17.1) | 14 (20.9) | ||
| O | 109 (47.2) | 82 (50.0) | 27 (40.3) | ||
| AB | 8 ( 3.5) | 7 ( 4.3) | 1 ( 1.5) | ||
| Hemoglobin [median (IQR)] | 11.2 (9.2, 12.8) | 11.5 (9.5, 13.0) | 10.5 (9.0, 12.2) | 0.075 | |
| Hemoglobin Baseline [median (IQR)] | 10.8 (9.2, 12.8) | 11.8 (9.7, 13.1) | 9.60 (8.40, 11.00) | < 0.001 | |
GIM: Gastric intestinal metaplasia; IQR: Interquartile range; AA: African Americans; BMI: Body mass index; PPI: Proton pump inhibitors.